Shabir Madhi to Immunogenicity, Vaccine
This is a "connection" page, showing publications Shabir Madhi has written about Immunogenicity, Vaccine.
Connection Strength
4,559
-
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
Score: 0,696
-
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
Score: 0,670
-
Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children. Vaccine. 2020 05 08; 38(22):3862-3868.
Score: 0,653
-
Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
Score: 0,228
-
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial. J Infect. 2024 Dec; 89(6):106285.
Score: 0,222
-
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial. Lancet Infect Dis. 2023 03; 23(3):295-306.
Score: 0,194
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0,179
-
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1899-1909.
Score: 0,176
-
Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020 07; 20(7):851-863.
Score: 0,163
-
Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants. Expert Rev Vaccines. 2019 07; 18(7):751-754.
Score: 0,154
-
Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines. Expert Rev Vaccines. 2018 07; 17(7):635-651.
Score: 0,145
-
Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
Score: 0,138
-
Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine. 2017 08 03; 35(34):4321-4329.
Score: 0,135
-
Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. Clin Infect Dis. 2017 Jun 15; 64(12):1773-1779.
Score: 0,134
-
Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016 08; 16(8):923-34.
Score: 0,124
-
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
Score: 0,057
-
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
Score: 0,056
-
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis. Health Technol Assess. 2024 Jul; 28(34):1-109.
Score: 0,055
-
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 08 11; 228(3):299-310.
Score: 0,051
-
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):501-517.
Score: 0,049
-
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis. 2022 Oct; 22(10):1472-1483.
Score: 0,048
-
Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine. 2021 09 15; 39(39):5513-5523.
Score: 0,045
-
Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Front Immunol. 2020; 11:1282.
Score: 0,041
-
Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020 02; 7(2):e91-e103.
Score: 0,040
-
Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis. Influenza Other Respir Viruses. 2019 09; 13(5):438-452.
Score: 0,038
-
Case-control vaccine effectiveness studies: Data collection, analysis and reporting results. Vaccine. 2017 06 05; 35(25):3303-3308.
Score: 0,033
-
Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017 06 05; 35(25):3295-3302.
Score: 0,033